Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aprepitant + dexamethasone + olanzapine + ondansetron
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of four drugs used primarily for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). Each component acts through different mechanisms to provide broad-spectrum antiemetic coverage. Aprepitant is a neurokinin-1 (NK-1) receptor antagonist, dexamethasone is a corticosteroid, olanzapine is an atypical antipsychotic with antiemetic properties, and ondansetron is a 5-HT3 receptor antagonist. The combination targets multiple pathways involved in nausea and vomiting associated with highly emetogenic chemotherapy regimens[2][3][4].
- Other names
- aprepitant/dexamethasone/olanzapine/ondansetronanti-emetic quadruple combination
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)HTR3A (5-hydroxytryptamine receptor 3A)GR (Glucocorticoid receptor)DRD2 (Dopamine D2 Receptor)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on aprepitant + dexamethasone + olanzapine + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aprepitant + dexamethasone + olanzapine + ondansetron.